Boston Scientific Corporation (NYSE:BSX) – Analysts at Jefferies Group reduced their FY2019 earnings estimates for Boston Scientific in a research note issued to investors on Wednesday. Jefferies Group analyst R. Denhoy now expects that the medical equipment provider will earn $1.49 per share for the year, down from their prior estimate of $1.51. Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for Boston Scientific’s FY2020 earnings at $1.63 EPS.

BSX has been the topic of several other reports. BidaskClub downgraded shares of Boston Scientific from a “hold” rating to a “sell” rating in a research report on Saturday, August 26th. BMO Capital Markets lifted their target price on shares of Boston Scientific from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research report on Monday, September 25th. Royal Bank Of Canada reissued a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a research report on Friday, September 1st. Finally, Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company. Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $30.97.

Boston Scientific (NYSE:BSX) traded up $0.30 during trading on Monday, hitting $25.24. 12,018,645 shares of the stock traded hands, compared to its average volume of 6,967,069. The stock has a market capitalization of $34,192.58, a P/E ratio of 20.41, a P/E/G ratio of 1.92 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. Boston Scientific has a 1-year low of $20.36 and a 1-year high of $29.93.

Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the consensus estimate of $0.31. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $0.27 earnings per share.

In other Boston Scientific news, EVP Timothy A. Pratt sold 11,061 shares of Boston Scientific stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $29.24, for a total value of $323,423.64. Following the completion of the sale, the executive vice president now directly owns 174,681 shares in the company, valued at $5,107,672.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $28.72, for a total transaction of $445,160.00. The disclosure for this sale can be found here. Insiders have sold 424,698 shares of company stock worth $12,273,553 over the last ninety days. 0.74% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Valeo Financial Advisors LLC acquired a new stake in Boston Scientific in the third quarter valued at approximately $138,000. Steward Partners Investment Advisory LLC acquired a new stake in Boston Scientific in the third quarter valued at approximately $139,000. Acrospire Investment Management LLC lifted its stake in Boston Scientific by 157.3% in the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 3,100 shares during the last quarter. Bronfman E.L. Rothschild L.P. lifted its stake in Boston Scientific by 14.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock valued at $160,000 after acquiring an additional 720 shares during the last quarter. Finally, San Francisco Sentry Investment Group CA acquired a new stake in shares of Boston Scientific in the second quarter worth $191,000. Hedge funds and other institutional investors own 90.57% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/jefferies-group-weighs-in-on-boston-scientific-corporations-fy2019-earnings-bsx/1748414.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.